# Torrent Pharma: how the business works

> For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Torrent Pharmaceuticals Limited · NSE: TORNTPHARM · BSE: 500420 · Sector: Healthcare

Updated for Q2 FY27 · checked 12 Nov 2026

This is the plain-text version of https://cityfort.in/stocks/torrent-pharma. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Torrent Pharma: how the business works", with the page URL.

## In short

Distributors, pharmacies and hospitals in more than 50 markets, most of all India, pay Torrent Pharma for its medicines; materials, running costs and staff take most of the money, and ₹15.6 of every ₹100 that came in was left as profit in FY26.

- In FY26 customers in India gave 58.4% of Torrent's revenue, the US 9.7%, Brazil 9.7%, Germany and Malta 8.9% and other countries 13.2%.
- Of every ₹100 that came in during FY26, ₹24.4 went on materials and goods bought, ₹24.2 on other running costs and ₹19.2 on staff.

## Key facts

**What does Torrent Pharma do?**

Torrent Pharmaceuticals Ltd is an Ahmedabad-based drug maker that sells branded medicines in India and Brazil and generic medicines in the US and Germany. Torrent Pharma's FY26 revenue from operations was ₹13,980 crore, and its FY26 annual report lists 8 manufacturing plants in India, not counting those that came with JB Pharma. [S1, S12]

**How does Torrent Pharma make money?**

Torrent Pharma sells medicines that doctors prescribe, mostly under its own brand names. By the FY26 annual report's business-unit figures, Torrent Pharma's India business sold ₹7,645 crore in FY26, Brazil ₹1,362 crore, the US ₹1,363 crore, Germany ₹1,249 crore and other markets ₹2,361 crore. [S1, S47]

**Who are Torrent Pharma's customers?**

By customer location, Torrent Pharma's FY26 revenue came 58.4% from customers in India, 9.7% from the US, 9.7% from Brazil, 8.9% from Germany and Malta and 13.2% from other countries. No single customer gave Torrent Pharma 10% or more of its revenue in FY26 or FY25. [S1]

**How big is Torrent Pharma?**

Torrent Pharma's FY26 revenue from operations was ₹13,980 crore and its profit for shareholders was ₹2,163 crore. Torrent Pharma had 18,531 employees at the end of FY26, not counting JB Pharma's staff. [S12, S1]

**Who owns Torrent Pharma?**

On 30 Sep 2026 Torrent Pharma's promoter group, led by the holding company Torrent Investments, held 60.78% of the shares. Foreign institutions held 17.22%, Indian institutions 13.46% (mutual funds 8.82%) and other shareholders 8.54%. No promoter shares were pledged. [S37, S1]

**What is Torrent Pharma's JB Pharma deal?**

Torrent Pharma bought control of J. B. Chemicals & Pharmaceuticals (JB Pharma) on 21 Jan 2026; by 3 Feb 2026 it had paid ₹12,537 crore for 48.80% of JB. JB Pharma then merged into Torrent Pharma with effect from 8 Jul 2026, and Torrent Pharma issued 41,922,416 new shares to JB's other shareholders on 20 Jul 2026. [S1, S43, S6]

**How did Torrent Pharma do in Q2 FY27?**

In Q2 FY27 (Jul–Sep 2026) Torrent Pharma's revenue was ₹4,979 crore, up from ₹3,302 crore a year earlier, and profit for shareholders was ₹534 crore, down from ₹591 crore. Q2 FY27 includes JB Pharma (₹1,086 crore of revenue) and Q2 FY26 does not; the company said its business excluding JB grew 18%. [S7, S17, S8]

**How much debt does Torrent Pharma have?**

On 30 Sep 2026 Torrent Pharma had borrowings of ₹13,874 crore and cash and liquid investments of ₹2,986 crore, against borrowings of ₹3,026 crore on 31 Mar 2025. India Ratings affirmed Torrent Pharma at IND AA+ and changed its outlook to Positive, the company told the exchanges on 7 Oct 2026. [S7, S20, S40]

**Why did Torrent Pharma's promoter holding fall to 60.78%?**

Torrent Pharma's promoter holding fell from 68.31% to 60.78% on 20 Jul 2026 because Torrent Pharma issued 41,922,416 new shares to JB Pharma's shareholders under the merger; the promoter group's 231,185,400 shares did not change. Earlier, on 30 Oct 2024, Torrent Investments sold 2.94% of Torrent Pharma, taking the holding from 71.25% to 68.31%. [S36, S37, S6, S42]

**What dividend does Torrent Pharma pay?**

Torrent Pharma's dividend for FY26 was ₹38 per share: an interim ₹29 and a final ₹9 recommended on 22 May 2026. That was 59.4% of Torrent Pharma's FY26 basic earnings per share of ₹63.92 (Cityfort calculation from the FY26 annual report). [S1, S13]

## What does Torrent Pharma sell?

Torrent makes medicines. In India and Brazil it sells them under its own brand names, which doctors prescribe. In the US and Germany it sells generics: cheaper copies of medicines whose patents have expired. Since 21 Jan 2026 it also owns JB Pharma's medicines.

- **Branded medicines in India:** Prescription brands, many for long-term conditions such as heart disease and diabetes: ₹7,645 crore of revenue in FY26, including JB Pharma from 21 Jan 2026. The FY26 annual report says Torrent with JB ranks 1st in heart medicines in India and 5th in the Indian medicine market overall. [S1, S47]
- **Branded generics in Brazil:** Medicines sold under brand names in Brazil: ₹1,362 crore in FY26. In Q2 FY27, 53 Torrent products were waiting for approval from ANVISA, Brazil's drug regulator. [S1, S8]
- **Generic medicines in the US:** Off-patent medicines sold to US buyers: ₹1,363 crore in FY26, and US$44 million in Q2 FY27. [S1, S8]
- **Generic medicines in Germany:** Off-patent medicines sold in Germany, part of them through tenders: ₹1,249 crore in FY26. Torrent entered Germany in 2005 by buying Pfizer's marketing arm there, Heumann. [S1, S8]
- **Other countries and contract manufacturing:** Medicines sold in other countries, and medicines made for other companies (contract manufacturing, including JB's): ₹2,361 crore in FY26, about 17% of revenue. [S1, S38]
- **The JB Pharma business:** JB's brands in India, its international sales and contract manufacturing: ₹1,086 crore of revenue in Q2 FY27, of which India prescription brands ₹597 crore and international business ₹406 crore. [S8]

## Who pays Torrent Pharma?

- **Customers in India (58.4% of revenue):** Wholesale distributors, stockists, pharmacies, online sellers and institutions such as hospitals, which sell to patients on doctors' prescriptions. Share is of FY26 revenue by customer location (₹8,161 crore); the India business unit reported ₹7,645 crore. [S1]
- **Customers in the US (9.7% of revenue):** Buyers of Torrent's generic medicines in the US: ₹1,363 crore in FY26, against ₹1,100 crore in FY25. [S1]
- **Customers in Brazil (9.7% of revenue):** Buyers of Torrent's branded generics in Brazil: ₹1,362 crore in FY26. [S1]
- **Customers in Germany and Malta (8.9% of revenue):** Buyers of Torrent's generic medicines in Germany, including through tenders: ₹1,249 crore in FY26. [S1, S8]
- **Customers in other countries (13.2% of revenue):** Buyers in more than 50 markets in all, and companies that pay for contract manufacturing: ₹1,845 crore in FY26. [S1]
- **Customer concentration:** No single customer gave Torrent 10% or more of its revenue in FY26 or FY25, according to its segment note. On 31 Mar 2025 one Latin America-based distributor owed more than 10% of trade receivables; none did on 31 Mar 2026. [S1]

## Where the money went (FY26)

1. In FY26 Torrent's medicines brought in ₹13,980 crore of revenue, including JB Pharma from 21 Jan 2026.
2. Other income was a net loss of ₹94 crore; foreign-exchange gains and losses are netted in it.
3. Materials and goods bought took ₹3,388 crore, employees ₹2,671 crore and other running costs ₹3,362 crore.
4. Depreciation and amortisation took ₹1,119 crore, interest ₹385 crore, one-off costs ₹89 crore and income tax ₹734 crore.
5. What was left for Torrent's shareholders was ₹2,163 crore of profit.

Sources: S12, S1, S6.

## Key numbers by year (₹ crore)

Financials: consolidated, ₹ crore. Financial year runs April to March (March year end). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (₹ per share) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY22 | 8,508 | 1,946 | 22.9% | 777 | 9.1% | 22.96 | 1,803 | 203 | 1,600 | S24, S5, S4 |
| FY23 | 9,620 | 2,842 | 29.5% | 1,245 | 12.9% | 36.79 | 2,368 | 574 | 1,794 | S23, S4 |
| FY24 | 10,728 | 3,456 | 32.2% | 1,656 | 15.4% | 48.94 | 3,266 | 433 | 2,833 | S22, S3 |
| FY25 | 11,516 | 3,697 | 32.1% | 1,911 | 16.6% | 56.47 | 2,585 | 611 | 1,974 | S20, S2 |
| FY26 | 13,980 | 4,470 | 32.0% | 2,163 | 15.5% | 63.92 | 3,023 | 677 | 2,346 | S12, S1 |

- EBITDA = profit before interest, tax and wear-and-tear of assets.
- Net profit is the share belonging to the company's owners.
- FY26: Total profit of ₹2,138 crore is ₹25 crore less than the shareholders' share because JB Pharma's minority shareholders took ₹25 crore of losses between 21 Jan and 31 Mar 2026.

## Balance sheet (as of 30 Sep 2026, ₹ crore)

On 30 Sep 2026 Torrent's borrowings were ₹10,888 crore more than its cash and liquid investments, down from ₹12,767 crore on 31 Mar 2026 (Cityfort calculation from the results); the company put net debt at 1.8 times EBITDA. [S7, S6, S12, S20, S1, S9, S11, S13, S38]

| Item | Value |
| --- | --- |
| Total debt | 13,874 |
| Cash and investments | 2,986 |
| Net debt (debt minus cash) | 10,888 |
| Net worth (shareholders' money) | 18,373 |
| Debt to equity (times) | 0.76 |

- Borrowings were ₹3,026 crore on 31 Mar 2025 and ₹14,798 crore on 31 Mar 2026; they include ₹10,990 crore of NCDs issued on 19 Jan 2026 for the JB deal. Lease liabilities are not included.
- Cash and liquid investments = cash, other bank balances and current investments. Debt to equity = borrowings ÷ net worth (Cityfort calculation).
- The company's own measure: net debt was 2.3 times EBITDA for FY26 (using JB's full-year EBITDA), 2.07 times at Q1 FY27 and 1.8 times at Q2 FY27.
- ICRA's own calculation put total debt at 3.3 times operating profit before depreciation, interest and tax for FY26, against 0.9 times for FY25.
- On 30 Sep 2026 goodwill was ₹3,990 crore and other intangible assets ₹23,352 crore, of total assets of ₹44,615 crore. Net worth rose from ₹8,389 crore on 31 Mar 2026 after the merger shares were issued and JB's minority stake was folded in.

## Who owns Torrent Pharma? (shareholding, Q2 FY27)

| Holder | % of shares |
| --- | --- |
| Promoters | 60.78% |
| Promoter shares pledged (% of promoter shares) | 0.0% |
| Foreign institutions (FII) | 17.22% |
| Indian institutions (DII) | 13.46% |
| Public | 8.54% |

Sources: S25, S26, S27, S28, S29, S30, S31, S32, S33, S34, S35, S36, S37, S42.

## What could go wrong

### Debt taken on for JB

Borrowings were ₹13,874 crore on 30 Sep 2026, against ₹3,026 crore on 31 Mar 2025. Interest cost was ₹300 crore in Q2 FY27, against ₹48 crore in Q2 FY26; the CFO put the average interest cost at about 7.6% in Feb 2026. [S7, S20, S17, S16, S9]

What to watch: Net debt each half-year (₹10,888 crore on 30 Sep 2026) and the company's net debt to EBITDA (1.8 times at Q2 FY27).

### Joining JB into Torrent

JB's revenue was largely flat at ₹1,086 crore in Q2 FY27 and its international business fell 7%. The company said merging sales teams, plants and quality systems had a "transient impact" and postponed some deliveries. [S8, S9, S49]

What to watch: JB revenue each quarter (₹1,201 crore in Q1 FY27, ₹1,086 crore in Q2 FY27).

### Amortisation and goodwill

Depreciation and amortisation was ₹609 crore in Q2 FY27, against ₹204 crore in Q2 FY26. On 30 Sep 2026 goodwill (₹3,990 crore) and other intangible assets (₹23,352 crore) together exceeded net worth of ₹18,373 crore. [S7, S17]

What to watch: Depreciation and amortisation each quarter, and any write-down of goodwill or intangibles.

### Lost tenders and a supplier problem in Germany

Germany revenue was €26 million in Q2 FY27, down 13% in constant currency. Sanjay Gupta cited the loss of high-value tenders and disruption at third-party suppliers. [S8, S9]

What to watch: Germany revenue in euros and its constant-currency growth each quarter.

### Waiting for approvals in Brazil

53 Torrent products were under review by ANVISA in Q2 FY27. Brazil revenue rose 3% in local currency in Q1 FY27, which the company linked to a one-time cut in channel stock, and 20% in Q2 FY27. [S8, S49]

What to watch: The number of products under ANVISA review and Brazil revenue in local currency.

### Relying on a partner for semaglutide injections

A manufacturing partner's supply problem kept Torrent's semaglutide injections off the market for nearly two months in 2026; a new partner restored supply by Sep 2026. Combined market share went from 36% in Q1 FY27 to 32% in Q2 FY27. [S11, S9]

What to watch: Semaglutide market share in each quarter's call.

### Currency swings

About 41% of FY26 revenue came from exports (BRSR). Other income, which nets foreign-exchange gains and losses, was negative in every quarter from Q4 FY25 to Q2 FY27 and −₹94 crore for FY26. [S1, S6, S7]

What to watch: Other income in each quarter's results (−₹10 crore in Q2 FY27).

## What to watch

Next: Q3 FY27 results, Date not announced yet.

- **JB's revenue:** JB brought in ₹1,086 crore in Q2 FY27, largely flat; the company called the integration impact transient.
- **Net debt and leverage:** Net debt was ₹10,888 crore on 30 Sep 2026, 1.8 times EBITDA by the company's measure; the CFO said in Feb 2026 he expected around 1 to 1.1 times in FY28.
- **Germany and semaglutide:** Germany revenue fell 13% in constant currency in Q2 FY27, and semaglutide market share went from 36% in Q1 FY27 to 32% in Q2 FY27.

## Sources

- S1: Integrated Annual Report 2025-26 (FY26). Torrent Pharmaceuticals Ltd (company IR site). https://www.torrentpharma.com/docs/Torrent_Pharma_IR_2026_Single_high_e091cb26e6.pdf (published 1 Jun 2026)
- S2: Annual Report 2024-25 (FY25). Torrent Pharmaceuticals Ltd (company IR site). https://torrentpharma.com/pdf/investors/AR-2024-25_Single_page_view.pdf (published 4 Jul 2025)
- S3: Annual Report 2023-24 (FY24). Torrent Pharmaceuticals Ltd (company IR site). https://www.torrentpharma.com/assets/Annual_Report_2023_24_Single_page_view_e83a64cdc8.pdf (published 29 Jun 2024)
- S4: Annual Report 2022-23 (FY23). Torrent Pharmaceuticals Ltd (company IR site). https://www.torrentpharma.com/assets/Annual_Report_2022_23_Single_page_view_6ce9daddfa.pdf (published 14 Jul 2023)
- S5: Annual Report 2021-22 (FY22). Torrent Pharmaceuticals Ltd (company IR site). https://www.torrentpharma.com/assets/AR_2021_22_3949a7db1f.pdf (published 4 Jul 2022)
- S6: Consolidated financial results, quarter and half year ended 30 Sep 2026 (Q2 FY27). Torrent Pharmaceuticals Ltd (company IR site). https://www.torrentpharma.com/docs/Consolidated_761b8a03f3.pdf (published 23 Oct 2026)
- S7: Integrated filing (financials) XBRL, consolidated, Q2 FY27. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1745044_23102026081509_WEB.xml (published 23 Oct 2026)
- S8: Press release: Torrent Pharma announces Q2 FY27 results. Torrent Pharmaceuticals Ltd (company IR site). https://www.torrentpharma.com/docs/Press_Release_ceca3763b1.pdf (published 23 Oct 2026)
- S9: Q2 FY27 earnings call transcript (call 23 Oct 2026). Torrent Pharmaceuticals Ltd (company IR site). https://torrentpharma.com/pdf/investors/Q2-FY26-27_Earnings-Call-Transcript.pdf (published 29 Oct 2026)
- S10: Integrated filing (financials) XBRL, consolidated, Q1 FY27. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1705312_30072026053512_WEB.xml (published 30 Jul 2026)
- S11: Q1 FY27 earnings call transcript (call 30 Jul 2026). Torrent Pharmaceuticals Ltd (company IR site). https://torrentpharma.com/pdf/investors/Q1-FY26-27_Earnings-Call-Transcript.pdf (published 4 Aug 2026)
- S12: Integrated filing (financials) XBRL, consolidated, Q4 FY26 and FY26. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1671721_22052026083819_WEB.xml (published 22 May 2026)
- S13: Q4 FY26 earnings call transcript (call 22 May 2026). Torrent Pharmaceuticals Ltd (company IR site). https://www.torrentpharma.com/pdf/investors/Q4-FY25-26_Earnings-Call-Transcript.pdf (published 26 May 2026)
- S14: Integrated filing (financials) XBRL, consolidated, Q3 FY26. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1625487_13022026065221_WEB.xml (published 13 Feb 2026)
- S15: Press release: Torrent Pharma announces Q3 FY26 results. Torrent Pharmaceuticals Ltd (company IR site). https://www.torrentpharma.com/docs/Press_Release_043505acc3.pdf (published 13 Feb 2026)
- S16: Q3 FY26 earnings call transcript (call 13 Feb 2026). Torrent Pharmaceuticals Ltd (company IR site). https://torrentpharma.com/pdf/investors/Q3-FY25-26_Earnings-Call-Transcript.pdf (published 20 Feb 2026)
- S17: Integrated filing (financials) XBRL, consolidated, Q2 FY26. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1568469_07112025071721_WEB.xml (published 7 Nov 2025)
- S18: Press release: Torrent Pharma announces Q2 FY26 results. Torrent Pharmaceuticals Ltd (company IR site). https://www.torrentpharma.com/docs/Press_Release_e78a00d91b.pdf (published 7 Nov 2025)
- S19: Integrated filing (financials) XBRL, consolidated, Q1 FY26. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1495351_28072025052225_WEB.xml (published 28 Jul 2025)
- S20: Integrated filing (financials) XBRL, consolidated, Q4 FY25 and FY25. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1444809_20052025074210_WEB.xml (published 20 May 2025)
- S21: Financial results XBRL, consolidated, Q3 FY25. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_117639_1360534_24012025053307.xml (published 24 Jan 2025)
- S22: Financial results XBRL, consolidated, Q4 FY24 and FY24. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_107101_1138062_24052024070903.xml (published 24 May 2024)
- S23: Financial results XBRL, consolidated, Q4 FY23 and FY23. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_93674_858897_30052023073710.xml (published 30 May 2023)
- S24: Financial results XBRL, consolidated, Q4 FY22 and FY22. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_85437_660893_25052022080444_WEB.xml (published 25 May 2022)
- S25: Shareholding pattern as of 31 Dec 2023. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/SHP_183973_1018211_12012024025402_WEB.xml (published 12 Jan 2024)
- S26: Shareholding pattern as of 31 Mar 2024. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/SHP_188025_1102768_19042024084244_WEB.xml (published 19 Apr 2024)
- S27: Shareholding pattern as of 30 Jun 2024. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/SHP_189289_1182688_12072024052256_WEB.xml (published 12 Jul 2024)
- S28: Shareholding pattern as of 30 Sep 2024. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/SHP_191721_1266867_11102024065135_WEB.xml (published 11 Oct 2024)
- S29: Shareholding pattern as of 31 Dec 2024. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/SHP_194895_1347516_16012025042708_WEB.xml (published 16 Jan 2025)
- S30: Shareholding pattern as of 31 Mar 2025. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/SHP_198233_1419252_18042025072033_WEB.xml (published 18 Apr 2025)
- S31: Shareholding pattern as of 30 Jun 2025. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1488083_19072025090817_WEB.xml (published 19 Jul 2025)
- S32: Shareholding pattern as of 30 Sep 2025. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1546746_13102025073956_WEB.xml (published 13 Oct 2025)
- S33: Shareholding pattern as of 31 Dec 2025. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1594668_03012026011705_WEB.xml (published 3 Jan 2026)
- S34: Shareholding pattern as of 31 Mar 2026. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1653365_17042026052714_WEB.xml (published 17 Apr 2026)
- S35: Shareholding pattern as of 30 Jun 2026. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1697244_20072026060641_WEB.xml (published 20 Jul 2026)
- S36: Shareholding pattern as of 20 Jul 2026 (capital change after JB merger allotment). National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1697348_20072026063703_WEB.xml (published 20 Jul 2026)
- S37: Shareholding pattern as of 30 Sep 2026. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1739383_15102026075118_WEB.xml (published 15 Oct 2026)
- S38: ICRA rationale: Torrent Pharmaceuticals Limited, change in limits (21 Jul 2026). ICRA Limited. https://www.icra.in/Rating/ShowRationalReportFilePdf/144325 (published 21 Jul 2026)
- S39: ICRA rationale: ratings reaffirmed; [ICRA]A1+ assigned for fresh CPs (5 Jan 2026, revised). ICRA Limited. https://www.icra.in/Rating/ShowRationalReportFilePdf/140133 (published 5 Jan 2026)
- S40: Intimation of credit rating: India Ratings affirms IND AA+, outlook revised to Positive. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/TORNTPHARM_07102026193222_SEIntimationIndiaRatings071026.pdf (published 7 Oct 2026)
- S41: NSE historical equity data, TORNTPHARM (EQ), 2 to 11 Nov 2026 (close on 11 Nov 2026). National Stock Exchange of India. https://www.nseindia.com/api/historicalOR/cm/equity?symbol=TORNTPHARM&series=[%22EQ%22]&from=01-11-2026&to=12-11-2026 (published 11 Nov 2026)
- S42: SAST Reg 29(2) disclosure: Torrent Investments sold 9,944,040 shares (2.94%) on 30 Oct 2024. National Stock Exchange of India (filed by Torrent Investments). https://nsearchives.nseindia.com/corporate/TORNTPHARM_10302024184206_42703.zip (published 30 Oct 2024)
- S43: Scheme of amalgamation of J. B. Chemicals & Pharmaceuticals with Torrent: effective date 8 Jul 2026. Torrent Pharmaceuticals Ltd (company IR site). https://www.torrentpharma.com/docs/02_Intimation_Of_Effective_Date_Of_Scheme_Of_Amalgamation_b3199d2259.pdf (published 8 Jul 2026)
- S44: Record date (17 Jul 2026) for JB Chemicals shareholders under the scheme of amalgamation. Torrent Pharmaceuticals Ltd (company IR site). https://www.torrentpharma.com/docs/03_Record_date_in_the_matter_of_Scheme_of_Amalgamation_f42061312e.pdf (published 7 Jul 2026)
- S45: Press release: Torrent Pharma agrees to acquire 3 anti-diabetes brands from Boehringer Ingelheim. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/TORNTPHARM_04122024181836_SEIntimationPR04122024.pdf (published 4 Dec 2024)
- S46: Change in senior management personnel: resignation of Executive Director Amal Kelshikar. National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/TORNTPHARM_16102026180229_SE_IntimationSMP.pdf (published 16 Oct 2026)
- S47: Investor presentation: audited results for Q4 FY26 and FY26 (filed with NSE). National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/TORNTPHARM_22052026165052_IP.pdf (published 22 May 2026)
- S48: Investor presentation: results for Q3 FY26 and 9M FY26 (filed with NSE). National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/TORNTPHARM_13022026170226_ip.pdf (published 13 Feb 2026)
- S49: Press release: Torrent Pharma announces Q1 FY27 results (with results filing). National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd). https://nsearchives.nseindia.com/corporate/TORNTPHARM_30072026165229_SE.pdf (published 30 Jul 2026)
